RaviPatelMD

Oncology • Bakersfield, CA

Associate Clinical Professor, Oncology, David Geffen School of Medicine at UCLA

Join to view full profile

Dr. Patel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Patel's full profile

Already have an account?

Office
6501 Truxtun Ave
Bakersfield, CA 93309
Phone+1 661-322-2206

Fax+1 661-327-7027

Education & Training

Loyola University Medical CenterFellowship, Hematology and Medical Oncology, 1983 - 1985
Advocate Health Care/Advocate Illinois Masonic Medical CenterResidency, Internal Medicine, 1980 - 1983
Government Medical College GujuratClass of 1978

Certifications & Licensure

CA State Medical License 1985 - 2025
IL State Medical License 1981 - 1987
IN State Medical License 1984 - 1986
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Fellow (FACP) American College of Physicians, 1995

Clinical Trials

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Start of enrollment: 2011 Apr 01
Terminated
Phase 3
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 1
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2014 May 01
Completed
Phase 2
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Start of enrollment: 2014 Sep 09
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

1264 citations
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2...
Richard S. Finn, John Crown, István Láng, Katalin Boér, Igor Bondarenko
The Lancet. Oncology. 2015-01-01
38 citations
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).
Sara A. Hurvitz, Jennifer L. Caswell-Jin, Katherine McNamara, Jason J. Zoeller, Gregory R. Bean
Nature Communications. 2020-11-17
84 citations
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- ad...
Richard S. Finn, Katalin Boér, Igor Bondarenko, Ravindranath Patel, Tamás Pintér
Breast Cancer Research and Treatment. 2020-07-18

Professional Memberships

American College of Physicians - ACP
Fellow